Towards this objective, we developed a bridging-lipid nanoparticle (B-LNP) with anti-CD47/PD-L1 dual-targeting capability to simultaneously block innate (CD47) and effector (PD-L1) checkpoint molecules while also delivering the STING agonist, diABZI, to TAMCs in GBM. This evidence concerns the gene CD274 and glioblastoma.